A Phase 1/2 interventional study of DFI205 bispecific antibody in Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc), sponsored by Diabetes Free, Inc.. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Diabetes Free, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 362 studies in Arthritis, Rheumatoid with a site in Germany — 27 open to participants now, 50 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.
Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 235th largest by planned enrollment of the 297 interventional ones that give a count, is one of 7 that started in 2026, is one of 17 in phase 1/2, reaches primary completion later than 33 of the 49 other live ones, and was the 361st registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →27 of the 362 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 8 more countries
Ages 18–65
Quell Therapeutics Limited · Sites in Germany, Spain, United Kingdom
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 3 more countries
Ages 18–75
AstraZeneca · Sites in Germany, United States, Argentina and 14 more countries
Ages 18+
Hoffmann-La Roche · Sites in Germany, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
362 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 108 · Phase 3 116 · Phase 4 22
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 259 across the 297 interventional studies, 585 across the 65 observational. Of the 305 that completed or were terminated, 198 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
327 of 362 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Diabetes Free, Inc. as lead sponsor.
Diabetes Free, Inc. has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
13 of the studies in Arthritis, Rheumatoid with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous (IV) infusion of DFI205 at ascending dose levels.
Drug: DFI205 bispecific antibody
DFI205 monthly IV infusions at the recommended Phase 2 dose
Drug: DFI205 bispecific antibody
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Numbers and types of all adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
Time to normalized peripheral blood B cell counts compared to baseline.
Time frame: Up to 1 year post-dosing
To monitor immune response to DFI205
Number of participants with anti-drug antibody development.
Time frame: Up to 1 year post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with RA
Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP \< 2.6, DAS28-ESR \<2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of \>5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline \>10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60)
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Change in tender joint count (TJC28) compared to baseline
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Change in swollen joint count (SJC28) compared to baseline
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Change in creatine phosphokinase (CPK) compared to baseline
Time frame: 24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Change in muscle strength (MMT8 score) compared to baseline
Time frame: 24 weeks post-dosing
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Time frame: Up to 1 year post-dosing
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Time frame: Up to 1 year post-dosing
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Time frame: Up to 1 year post-dosing
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Time frame: Up to 1 year post-dosing
To investigate the pharmacokinetics of DFI205
Blood samples will be collected to quantitate serum concentrations of DFI205
Time frame: Up to 1 year post-dosing
To investigate the pharmacodynamics of DFI205 in blood
Proportions of immune cell subsets in blood by FACS analysis over the course of the study.
Time frame: Up to 1 year post-dosing
To investigate the secondary lymphoid system pharmacodynamics of DFI205
Proportions of disease-specific lymph node cell populations over the course of the study.
Time frame: Up to 1 year post-dosing
To investigate soluble CD40 pharmacodynamics of DFI205
Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments.
Time frame: Up to 1 year post-dosing
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.
Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.